GO:2000424 positive regulation of eosinophil chemotaxis: Immune Cell Recruitment Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000424 describes any process that activates or increases the frequency, rate or extent of eosinophil chemotaxis, a key step in allergic and type 2 immune responses.
• Eosinophil chemotaxis is positively regulated by chemokines such as CCL26 (eotaxin-3), which is induced by glycolysis in chronic rhinosinusitis with nasal polyps.
• Negative regulators like CXCL9 (Mig) and lactoferrin can suppress eosinophil recruitment, highlighting the balance of positive and negative signals.
• SPINK5 has been identified as a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma, linking eosinophil activity to cancer biology.
• Eosinophil chemoattractants are elevated in eosinophilic otitis media, demonstrating the clinical relevance of this process in ear inflammation.
• The CXCL3/CXCL5/CXCR2 axis regulates type 2 responses in asthma exacerbation, indirectly influencing eosinophil recruitment.
Description
Eosinophils are granulocytic leukocytes that play a central role in allergic inflammation, asthma, and host defense against parasites. Their directed migration, or chemotaxis, toward sites of inflammation is a tightly regulated process. The Gene Ontology term GO:2000424, positive regulation of eosinophil chemotaxis, encompasses any process that activates or increases the frequency, rate, or extent of eosinophil chemotaxis. This term is critical for understanding how eosinophils are recruited to tissues in diseases such as asthma, eosinophilic chronic rhinosinusitis, and eosinophilic otitis media. Research into this process has identified multiple positive regulators, including the chemokine CCL26 (eotaxin-3), which is induced by glycolysis in nasal polyp tissues and promotes eosinophil migration. Conversely, negative regulators such as CXCL9 (Mig) and lactoferrin can inhibit eosinophil recruitment, underscoring the importance of balanced regulation. The clinical relevance of this GO term is further highlighted by its association with primary atopic disorders, where rapid genomic sequencing can identify underlying mutations. Understanding the molecular players and signaling pathways that positively regulate eosinophil chemotaxis is essential for developing targeted therapies for eosinophilic inflammatory diseases. This article synthesizes current knowledge from authoritative QuickGO annotations and published literature to provide a comprehensive overview of GO:2000424, its mechanisms, key genes, and research methodologies.
positive regulation of eosinophil chemotaxis At A Glance
| GO ID | GO:2000424 |
|---|---|
| GO term | positive regulation of eosinophil chemotaxis |
| Ontology | biological_process |
| Synonym | None |
| Major function | Activates or increases the directed migration of eosinophils toward chemical signals |
| Parent term | positive regulation of chemotaxis (GO:0050921) |
| Related term | eosinophil chemotaxis (GO:0048245) |
| Cellular location | Extracellular space, plasma membrane, cytoplasm |
| Key molecules | CCL26, CXCL9, lactoferrin, SPINK5, CXCL3/CXCL5/CXCR2 |
What Is GO:2000424?
GO:2000424 is defined as any biological process that activates or increases the frequency, rate, or extent of eosinophil chemotaxis. In simpler terms, it includes all the signals and molecular events that tell eosinophils to move toward a specific location more quickly or in greater numbers. This term is a child of positive regulation of chemotaxis and is specific to eosinophils, a type of white blood cell involved in allergic reactions and asthma.
Why Is positive regulation of eosinophil chemotaxis Important in Cell Biology?
Positive regulation of eosinophil chemotaxis is a fundamental process in type 2 immunity and allergic inflammation. Dysregulation of this process leads to excessive eosinophil accumulation in tissues, which is a hallmark of asthma, eosinophilic chronic rhinosinusitis, eosinophilic otitis media, and other atopic disorders. Understanding the positive regulators of eosinophil chemotaxis can reveal therapeutic targets to dampen harmful eosinophilic inflammation while preserving beneficial immune responses. Moreover, recent studies link eosinophil activity to cancer, as seen with SPINK5 regulation of eosinophil extracellular traps in head and neck squamous cell carcinoma. Therefore, this GO term is important for both basic immunology and clinical translation.
• Eosinophil chemotaxis is central to allergic asthma pathogenesis, where eosinophils cause airway inflammation and remodeling.
• Positive regulation by CCL26 in chronic rhinosinusitis with nasal polyps highlights a direct link to a common chronic inflammatory disease.
• Eosinophilic otitis media involves elevated chemoattractants, making this process a target for treating middle ear inflammation.
• Primary atopic disorders can result from mutations affecting eosinophil regulation, and genomic sequencing aids diagnosis.
• Negative regulators like CXCL9 and lactoferrin provide natural brakes on eosinophil recruitment, offering therapeutic potential.
• SPINK5 regulation of eosinophil extracellular traps in head and neck cancer suggests a role in tumor immunity.
• The CXCL3/CXCL5/CXCR2 axis modulates type 2 responses in asthma exacerbation, indirectly impacting eosinophil chemotaxis.
• GM-CSF levels in asthmatic patients infected with respiratory syncytial virus may influence eosinophil activity.
• Understanding positive regulation can guide development of drugs that block eosinophil recruitment in allergic diseases.
• This GO term is a key annotation for functional genomics studies of inflammatory diseases.
What Happens During positive regulation of eosinophil chemotaxis?
Chemokine-mediated activation
In simple terms: Chemical signals called chemokines tell eosinophils to start moving.
Positive regulation of eosinophil chemotaxis often begins with chemokines such as CCL26 (eotaxin-3) binding to CCR3 receptors on eosinophils. In eosinophilic chronic rhinosinusitis with nasal polyps, glycolysis-induced CCL26 expression enhances eosinophil migration, and vitamin D can impede this process by inhibiting glycolysis. Similarly, in eosinophilic otitis media, multiple chemoattractants are elevated, promoting eosinophil recruitment.
Signal transduction and cytoskeletal rearrangement
In simple terms: Inside the cell, signals cause the skeleton to change shape so the cell can move.
Upon chemokine binding, intracellular signaling pathways activate Rho GTPases and actin polymerization, leading to cytoskeletal rearrangement and directional movement. This process is positively regulated by factors that amplify these signals. For example, the CXCL3/CXCL5/CXCR2 axis can modulate type 2 responses in asthma exacerbation, indirectly promoting eosinophil chemotaxis.
Integrin activation and adhesion
In simple terms: Eosinophils must stick to blood vessel walls to crawl out into tissues.
Positive regulation also involves integrin activation, which allows eosinophils to adhere to endothelial cells and migrate through tissues. Lactoferrin has been shown to inhibit eosinophil migration, indicating that positive regulators counteract such inhibitory signals. The balance between positive and negative signals determines the extent of eosinophil recruitment.
Amplification by cytokines and growth factors
In simple terms: Other immune molecules can boost the movement signal.
Cytokines such as GM-CSF can enhance eosinophil survival and activation, potentially amplifying chemotactic responses. In asthmatic patients infected with respiratory syncytial virus, GM-CSF levels are elevated, which may contribute to eosinophil recruitment. Additionally, SPINK5 regulates eosinophil extracellular traps in head and neck squamous cell carcinoma, linking eosinophil activity to tumor microenvironment.
Negative feedback and resolution
In simple terms: The body also has ways to stop eosinophils from moving too much.
Negative regulators like CXCL9 (Mig) can inhibit eosinophil recruitment to the lung, as shown in a mouse model. This negative feedback is crucial to prevent excessive tissue damage. Understanding these counter-regulatory mechanisms is essential for therapeutic targeting of positive regulation.
Key Genes Involved in GO:2000424 positive regulation of eosinophil chemotaxis
The following genes and proteins are key players in the positive regulation of eosinophil chemotaxis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCL26 | Chemokine that attracts eosinophils via CCR3 | Induced by glycolysis in nasal polyps; target for vitamin D intervention |
| CXCL9 | Negative regulator of eosinophil recruitment | Inhibits eosinophil migration to lung in mouse models |
| LTF | Lactoferrin inhibits eosinophil migration | Potential anti-inflammatory agent |
| SPINK5 | Regulates eosinophil extracellular traps | Linked to head and neck squamous cell carcinoma |
| CXCL3 | Neutrophilic chemokine, modulates type 2 responses | Involved in asthma exacerbation |
| CXCL5 | Neutrophilic chemokine, modulates type 2 responses | Involved in asthma exacerbation |
| CXCR2 | Receptor for CXCL3/CXCL5 | Mediates neutrophilic axis affecting eosinophils |
| GM-CSF | Cytokine that enhances eosinophil survival and activation | Elevated in asthmatic patients with RSV infection |
| CCR3 | Receptor for CCL26 on eosinophils | Mediates chemotaxis |
| IL-5 | Cytokine that promotes eosinophil differentiation and activation | Indirectly supports chemotaxis |
| IL-13 | Cytokine that induces CCL26 expression | Drives eosinophilic inflammation |
| IL-4 | Cytokine that induces CCL26 expression | Drives eosinophilic inflammation |
| VCAM-1 | Adhesion molecule for eosinophil extravasation | Facilitates chemotaxis |
| ICAM-1 | Adhesion molecule for eosinophil extravasation | Facilitates chemotaxis |
| RhoA | GTPase involved in cytoskeletal rearrangement | Mediates chemotactic signaling |
| Rac1 | GTPase involved in cytoskeletal rearrangement | Mediates chemotactic signaling |
| PI3K | Kinase in chemokine signaling | Amplifies chemotactic signals |
How Is positive regulation of eosinophil chemotaxis Regulated?
The positive regulation of eosinophil chemotaxis is controlled by a balance of stimulatory and inhibitory signals. Pro-inflammatory cytokines such as IL-4 and IL-13 induce the expression of CCL26 in epithelial cells, which then attracts eosinophils. Glycolysis is a key metabolic pathway that supports CCL26 expression, and inhibition of glycolysis by vitamin D reduces eosinophil chemotaxis. Negative regulators include CXCL9, which binds to CXCR3 on eosinophils and inhibits their recruitment to the lung. Lactoferrin also inhibits eosinophil migration, possibly by interfering with chemokine receptors. Additionally, the CXCL3/CXCL5/CXCR2 axis can modulate type 2 responses, indirectly affecting eosinophil chemotaxis. GM-CSF, elevated in RSV-infected asthmatics, may enhance eosinophil activation and chemotaxis. These regulatory mechanisms ensure that eosinophil recruitment is tightly controlled to prevent excessive tissue damage.
positive regulation of eosinophil chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CCL26 | Eosinophilic chronic rhinosinusitis with nasal polyps | Knockout of CCL26 in nasal epithelial cells; overexpression in vitro |
| CXCL9 | Asthma, lung inflammation | Knockout mouse model of allergic airway inflammation |
| SPINK5 | Head and neck squamous cell carcinoma | Knockout in cancer cell lines; xenograft models |
| CXCL3/CXCL5 | Asthma exacerbation | Knockout mice or receptor antagonists in rhinovirus-induced asthma models |
| GM-CSF | Asthma with RSV infection | Overexpression in airway epithelial cells; knockout mice |
Eosinophilic chronic rhinosinusitis with nasal polyps
In eosinophilic chronic rhinosinusitis with nasal polyps, glycolysis-induced CCL26 expression promotes eosinophil chemotaxis, leading to tissue eosinophilia. Vitamin D can impede this process by inhibiting glycolysis, suggesting a potential therapeutic approach.
Asthma exacerbation
The CXCL3/CXCL5/CXCR2 neutrophilic chemotactic axis plays a critical role in regulating type 2 responses in a model of rhinovirus-induced asthma exacerbation. This axis can indirectly enhance eosinophil recruitment, contributing to airway inflammation. Additionally, GM-CSF levels are elevated in asthmatic patients infected with respiratory syncytial virus, which may further promote eosinophil chemotaxis.
Eosinophilic otitis media
Eosinophilic otitis media is characterized by elevated levels of eosinophil chemoattractants in the middle ear, leading to eosinophil accumulation and inflammation. This highlights the clinical importance of positive regulation of eosinophil chemotaxis in ear diseases.
Head and neck squamous cell carcinoma
SPINK5 has been identified as a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma. This suggests that eosinophil chemotaxis and activation may influence tumor progression and immune responses in cancer.
From positive regulation of eosinophil chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CCL26 positively regulate eosinophil chemotaxis? | CCL26 knockout or overexpression in epithelial cells, followed by chemotaxis assays |
| What is the role of CXCL9 in inhibiting eosinophil recruitment? | CXCL9 knockout mouse model of allergic lung inflammation |
| How does SPINK5 regulate eosinophil extracellular traps? | SPINK5 knockout in head and neck cancer cell lines |
| Does the CXCL3/CXCL5/CXCR2 axis modulate eosinophil chemotaxis? | CXCR2 knockout mice in rhinovirus-induced asthma model |
| What is the effect of GM-CSF on eosinophil chemotaxis in RSV infection? | GM-CSF overexpression or knockout in airway epithelial cells |
| Can vitamin D inhibit eosinophil chemotaxis via glycolysis? | In vitro glycolysis inhibition assays with CCL26 readout |
How to Study the positive regulation of eosinophil chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Directed migration of eosinophils | Testing chemoattractants like CCL26 |
| Genomic sequencing | Mutations in genes related to atopic disorders | Diagnosis of primary atopic disorders |
| Flow cytometry | Eosinophil count and surface markers | Quantifying eosinophils in tissues |
| Mouse models of asthma | Eosinophil recruitment to lungs | Testing gene knockouts |
| ELISA | Chemokine levels (e.g., CCL26, CXCL9) | Measuring expression in patient samples |
| Immunohistochemistry | Tissue eosinophil infiltration | Localizing eosinophils in biopsies |
| CRISPR knockout | Gene function in chemotaxis | Validating candidate regulators |
| RNA-seq | Transcriptional changes during chemotaxis | Identifying novel regulators |
In vitro chemotaxis assays
Transwell or Boyden chamber assays are commonly used to measure eosinophil migration toward chemoattractants such as CCL26. These assays can be combined with gene knockout or overexpression to study positive regulators.
Genomic sequencing for primary atopic disorders
Rapid identification of primary atopic disorders can be achieved by clinical landmark-guided, upfront genomic sequencing, which may reveal mutations in genes regulating eosinophil chemotaxis.
Flow cytometry and eosinophil quantification
Flow cytometry can quantify eosinophil numbers and activation markers in tissues or blood, providing insights into the extent of chemotaxis in vivo.
Animal models of allergic inflammation
Mouse models of asthma or eosinophilic inflammation are used to study the role of specific genes in eosinophil recruitment. Knockout or transgenic mice can be generated to test causality.
How CRISPR Can Be Used to Study GO:2000424 positive regulation of eosinophil chemotaxis
Knockout
CRISPR knockout of genes such as CCL26 or SPINK5 can be used to determine their necessity in positive regulation of eosinophil chemotaxis. For example, knocking out CCL26 in nasal epithelial cells would reduce eosinophil migration in vitro.
Point Mutation
Introducing point mutations in chemokine receptors like CCR3 or signaling molecules can help dissect specific residues required for positive regulation. This approach can reveal gain-of-function or loss-of-function variants.
Knock-in
Knock-in of tagged versions of CCL26 or CXCL9 can enable tracking of their expression and secretion in live cells, providing insights into their role in eosinophil chemotaxis.
Overexpression
Overexpression of positive regulators such as CCL26 or GM-CSF in cell lines or mouse models can enhance eosinophil chemotaxis, confirming their sufficiency. This is useful for studying downstream signaling.
How EDITGENE Supports positive regulation of eosinophil chemotaxis Research
Researchers studying positive regulation of eosinophil chemotaxis-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated. Functional validation through precise genome editing is essential to establish causality and explore therapeutic potential.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of eosinophil chemotaxis research.
Frequently Asked Questions About positive regulation of eosinophil chemotaxis
What is GO:2000424?
GO:2000424 is a Gene Ontology term for any process that activates or increases the frequency, rate or extent of eosinophil chemotaxis, which is the directed movement of eosinophils toward chemical signals.
What genes are involved in positive regulation of eosinophil chemotaxis?
Key genes include CCL26, CXCL9, SPINK5, CXCL3, CXCL5, CXCR2, and GM-CSF, among others.
How does CCL26 regulate eosinophil chemotaxis?
CCL26 (eotaxin-3) binds to CCR3 on eosinophils and promotes their migration. Its expression is induced by glycolysis in nasal polyps, and vitamin D can inhibit this process.
What diseases are associated with eosinophil chemotaxis?
Diseases include eosinophilic chronic rhinosinusitis with nasal polyps, asthma, eosinophilic otitis media, and head and neck squamous cell carcinoma.
How can I study positive regulation of eosinophil chemotaxis in the lab?
Common methods include Transwell chemotaxis assays, CRISPR knockout of candidate genes, flow cytometry, and mouse models of allergic inflammation.
What is the role of CXCL9 in eosinophil chemotaxis?
CXCL9 (Mig) negatively regulates eosinophil recruitment to the lung, acting as an inhibitory signal.
Does vitamin D affect eosinophil chemotaxis?
Yes, vitamin D impedes eosinophil chemotaxis by inhibiting glycolysis-induced CCL26 expression in eosinophilic chronic rhinosinusitis with nasal polyps.
What is the connection between SPINK5 and eosinophils?
SPINK5 is a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma, linking eosinophil activity to cancer.
How does GM-CSF influence eosinophil chemotaxis?
GM-CSF enhances eosinophil survival and activation, and elevated levels in asthmatic patients with RSV infection may promote eosinophil chemotaxis.
What CRISPR services are available for studying eosinophil chemotaxis?
EDITGENE offers knockout, point mutation, knock-in, overexpression models, CRISPR library screening, and bioinformatics services to study genes involved in eosinophil chemotaxis.
Conclusion
GO:2000424, positive regulation of eosinophil chemotaxis, is a critical biological process in allergic inflammation and type 2 immunity. Key regulators such as CCL26, CXCL9, and SPINK5 modulate eosinophil recruitment in diseases like asthma, chronic rhinosinusitis, and cancer. Understanding these mechanisms offers opportunities for therapeutic intervention. Advanced CRISPR tools and genomic approaches are essential for dissecting the causal roles of specific genes. EDITGENE provides comprehensive services to support such research, from knockout models to library screening.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Huang W et al.. 2025. Vitamin D impedes eosinophil chemotaxis via inhibiting glycolysis-induced CCL26 expression in eosinophilic chronic rhinosinusitis with nasal polyps.. Cell Commun Signal 23(1):104 PMID: 39985085
- 3. Fulkerson PC et al.. 2004. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9).. Proc Natl Acad Sci U S A 101(7):1987-92 PMID: 14769916
- 4. Bournazou I et al.. 2010. Inhibition of eosinophil migration by lactoferrin.. Immunol Cell Biol 88(2):220-3 PMID: 19918259
- 5. Zhao C et al.. 2024. SPINK5 is a key regulator of eosinophil extracellular traps in head and neck squamous cell carcinoma.. Discov Oncol 15(1):627 PMID: 39508915
- 6. Iino Y et al.. 2005. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.. Clin Exp Allergy 35(10):1370-6 PMID: 16238798
- 7. Sokulsky LA et al.. 2020. A Critical Role for the CXCL3/CXCL5/CXCR2 Neutrophilic Chemotactic Axis in the Regulation of Type 2 Responses in a Model of Rhinoviral-Induced Asthma Exacerbation.. J Immunol 205(9):2468-2478 PMID: 32948685
- 8. Abdullah SF. 2021. Granulocyte-Macrophage colony stimulating factor in asthmatic patients infected with respiratory syncytial virus.. Med J Malaysia 76(2):177-182 PMID: 33742625
